Gary Middleton
A5037541807- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Immune Cell Function and Interaction
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Immunotherapy and Immune Responses
- Genetic factors in colorectal cancer
- CAR-T cell therapy research
- Cytokine Signaling Pathways and Interactions
- Lung Cancer Research Studies
- Cancer Research and Treatments
- Lung Cancer Diagnosis and Treatment
- COVID-19 and healthcare impacts
- Cardiac Imaging and Diagnostics
- Colorectal and Anal Carcinomas
- Cancer Treatment and Pharmacology
- Occupational and environmental lung diseases
- Medical Imaging Techniques and Applications
- Esophageal Cancer Research and Treatment
- Immune cells in cancer
- Neuroendocrine Tumor Research Advances
- Cholangiocarcinoma and Gallbladder Cancer Studies
- RNA modifications and cancer
University of Birmingham
2016-2025
University Hospitals Birmingham NHS Foundation Trust
2014-2025
Munson Medical Center
2025
NIHR Surgical Reconstruction and Microbiology Research Centre
2015-2023
Queen Elizabeth Hospital Birmingham
2016-2023
Institute of Immunology
2015-2023
Heart of England NHS Foundation Trust
2023
Cancer Research UK Clinical Trials Unit
2022
Universität Hamburg
2020
University Medical Center Hamburg-Eppendorf
2020
We evaluated capecitabine (an oral fluoropyrimidine) and oxaliplatin (a platinum compound) as alternatives to infused fluorouracil cisplatin, respectively, for untreated advanced esophagogastric cancer.
Among patients with non-small-cell lung cancer (NSCLC), data on intratumor heterogeneity and genome evolution have been limited to small retrospective cohorts. We wanted prospectively investigate in relation clinical outcome determine the clonal nature of driver events evolutionary processes early-stage NSCLC.
BackgroundThe ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than 5-fluorouracil/folinic acid in patients with resected pancreatic cancer. Other clinical trials have shown better tumour response capecitabine alone advanced or metastatic We aimed determine efficacy safety compared monotherapy for cancer.MethodsWe did a phase 3, two-group, open-label, multicentre, randomised at 92 hospitals England, Scotland, Wales,...
To determine whether adding cetuximab to irinotecan prolongs survival in patients with metastatic colorectal cancer (mCRC) previously treated fluoropyrimidine and oxaliplatin.This multicenter, open-label, phase III study randomly assigned 1,298 epidermal growth factor receptor-expressing mCRC who had experienced first-line oxaliplatin treatment failure (400 mg/m(2) day 1 followed by 250 weekly) plus (350 every 3 weeks) or alone. Primary end point was overall (OS); secondary points included...
Community-based approaches to healthcare improvement are receiving increasing attention.Such could offer an infrastructure for efficient knowledge-sharing and a potent means of influencing behaviours, but their potential is yet be optimised.After briefly reviewing challenges communitybased approaches, we describe in detail the clinical community model.Through exploring communities practice, seek identify practical lessons optimising this community-based approach improvement.Through...
We undertook a comprehensive analysis of circulating myeloid-derived suppressor cells (MDSCs) and T regulatory (Tregs) in pancreatic, esophageal gastric cancer patients investigated whether MDSCs are an independent prognostic factor for survival. evaluated series plasma cytokines particular re-evaluated the Th2 cytokine interleukin-13 (IL-13). Peripheral blood was collected from 131 (46 60 25 gastric) 54 healthy controls. PBMC were harvested with subsequent flow cytometric MDSC (HLADR(-)...
Abstract Although BRAF inhibitor monotherapy yields response rates >50% in BRAFV600-mutant melanoma, only approximately 5% of patients with BRAFV600E colorectal cancer respond. Preclinical studies suggest that the lack efficacy is due to adaptive feedback reactivation MAPK signaling, often mediated by EGFR. This clinical trial evaluated and EGFR inhibition dabrafenib (D) + panitumumab (P) ± MEK trametinib (T) achieve greater suppression improved 142 cancer. Confirmed for D+P, D+T+P,...
BackgroundTherapeutic antibodies targeting EGFR have activity in advanced colorectal cancer, but results from clinical trials are inconsistent and the population which most benefit is derived uncertain. Our aim was to assess addition of panitumumab irinotecan pretreated cancer.MethodsIn this open-label, randomised trial, we enrolled patients who had cancer progressing after fluoropyrimidine treatment with or without oxaliplatin 60 centres UK. From December, 2006 until June, 2008, molecularly...
Data suggest selective internal radiotherapy (SIRT) in third-line or subsequent therapy for metastatic colorectal cancer has clinical benefit patients with liver metastases liver-dominant disease after chemotherapy. The FOXFIRE, SIRFLOX, and FOXFIRE-Global randomised studies evaluated the efficacy of combining first-line chemotherapy SIRT using yttrium-90 resin microspheres metastases. were designed combined analysis overall survival.
TRACERx, a prospective study of patients with primary non-small cell lung cancer, aims to map the genomic landscape cancer by tracking clonal heterogeneity and tumour evolution from diagnosis relapse.
The patterns of disease recurrence after resection pancreatic ductal adenocarcinoma with adjuvant chemotherapy remain unclear.
Lung cancer is the leading cause of cancer-associated mortality worldwide
Metastatic disease is responsible for the majority of cancer-related deaths
Abstract Intratumour heterogeneity (ITH) fuels lung cancer evolution, which leads to immune evasion and resistance therapy 1 . Here, using paired whole-exome RNA sequencing data, we investigate intratumour transcriptomic diversity in 354 non-small cell tumours from 347 out of the first 421 patients prospectively recruited into TRACERx study 2,3 Analyses 947 tumour regions, representing both primary metastatic disease, alongside 96 tumour-adjacent normal tissue samples implicate transcriptome...
People with cancer are at increased risk of hospitalisation and death following infection SARS-CoV-2. Therefore, we aimed to conduct one the first evaluations vaccine effectiveness against breakthrough SARS-CoV-2 infections in patients a population level.